Glipride M2 Forte Tablet is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. This dual-action formulation is prescribed when monotherapy with either agent is insufficient to achieve optimal glycemic targets. Glipride M2 Forte is typically administered once daily with meals to minimize gastrointestinal side effects associated with Metformin, such as nausea and diarrhea. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia, as these may increase the risk of lactic acidosis, a rare but serious adverse effect of Metformin. Additionally, Glimepiride may cause hypoglycemia, necessitating patient education on recognizing symptoms and appropriate management. This combination therapy should be used alongside diet and exercise to optimize glycemic control and reduce the risk of diabetes-related complications.